About Us
NKGen Biotech’s mission is to become the global leader in natural killer cell therapy.
Stephen Chen, MBA
CEO (Interim)
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in the immune-oncology space and are passionate and excited about the work we are doing to strengthen the immune system.
Senior Leadership
Yongman Kim, PhD
Chief Scientific Officer, Chief Innovation Officer
Will de Groot, MBA
Chief Business Officer
Philip Moody
Chief Financial Officer
Steven Cha, MD
Chief Medical Officer
Board of Directors
Sangwoo Park
Chairman and Founder
Stephen Chen, MBA
CEO (Interim)
Management Team
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
Hazel Cheng, PhD
Vice President of Alliance Management
Kim Beaudette
Director, Human Resources
Lucia Hui, CLS, MLS(ASCP), CM
Senior Director, Clinical Laboratory Operations
Yoonmi Kang
Assistant Director, Manufacturing